Nutex Health, Inc. (NUTX)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$193.24-2.25%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · NUTX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 0% of the last 1 guided quarters · -46.6% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue expanding hospital network with planned openings of three new hospitals in 2026 to drive patient volume and revenue growth.
Stated as a priority in 2 of last 2 quarters. Management reiterated plans to open three new hospitals in 2026 to sustain growth. This aligns with operational progress and solid financial results, including increased net income and operating income in 2026-Q1 and Q2. The trajectory is delivering as planned with hospital expansion underway.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We believe we are set up well for finishing the year strong as we continue to grow with the expected opening of three new hospital later this year”
“We remain on track to target a sustainable development pace of three to five hospitals annually”
Focus on increasing operating income and net income through cost management and operational efficiencies.
Stated as a priority in 2 of last 2 quarters. Operating income rose significantly from $114.3 million in first half 2025 to $203.0 million in first half 2026, supported by lower operating costs. The trajectory shows strong delivery on improving profitability and operating income.
“Operating income increasing to $203.0 million for the first six months of 2026 from $114.3 million in the same period of 2025”
“Operating income of $81.3 million compared to $80.7 million in prior year quarter”
Deliver diluted earnings per share of $15.87 for fiscal year 2026 as a key financial goal.
Stated as a priority in 2 of last 2 quarters. Diluted EPS was $6.52 in Q1 2026 and $9.38 in Q2 2026, supporting the full-year guidance of $15.87. The trajectory is delivering toward the EPS target with strong net income growth.
“Diluted EPS of $15.87 per share for first six months of 2026”
“Diluted EPS of $6.52 per share for the three months ended March 31, 2026”
Improve internal processes and reduce contract services expenses through favorable amendments and regulatory changes.
Newly stated in 2026-Q2. Contract services expense decreased by $52.3 million in Q2 2026 due to a retroactive amendment with HaloMD and CMS fee reduction, leading to an anticipated 25-30% ongoing reduction. This reflects substantive delivery on cost reduction in arbitration-related expenses.
“Total arbitration-related costs decreased by $52.3 million due to favorable amendment and CMS fee reduction”
Management aims to achieve a diluted EPS of $6.52 for the fiscal year 2026.
Over the trailing year it converted 4.34x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 55% of the time over the next year (vs 45% for the rest of the cohort, n=2490).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.